Clinical Research Papers:
Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF NRAS and EGFR evaluation
PDF | Full Text | How to cite
Metrics: PDF 2053 views | Full Text 2423 views
Alessandra Ulivieri1,2, Giuseppe Cardillo3, Liborio Manente1, Gregorino Paone4, Andrea Petricca Mancuso5, Leonardo Vigna5, Enrico Di Stasio6, Rita Gasbarra1, Salvatore Girlando7, Alvaro Leone1
1Anatomic Pathology Unit, San Camillo-Forlanini Hospitals, Rome, Italy
2Laboratory of Biomedical research “Fondazione Niccolò Cusano per la Ricerca Medico-Scientifica” Niccolò Cusano University of Rome, Rome, Italy
3Thoracic Surgery Unit, San Camillo-Forlanini Hospitals, Rome, Italy
4Department of Respiratory Diseases, San Camillo-Forlanini Hospitals, Rome, Italy
5Department of Medical Oncology, San Camillo-Forlanini Hospitals, Rome, Italy
6Institute of Biochemistry and Clinical Biochemistry, Università Cattolica del Sacro Cuore, Rome, Italy
7Anatomic Pathology Unit, S. Chiara Hospital, Trento, Italy
Correspondence to:
Alvaro Leone, e-mail: [email protected]
Keywords: Pathology, melanoma, pulmonary metastases, BRAF, NRAS, EGFR
Received: May 15, 2015 Accepted: June 20, 2015 Published: July 04, 2015
ABSTRACT
Background: Melanoma is highly curable in early stages but holds devastating consequences in advanced phases with a median survival of 6–10 months. Lungs are a common metastasis target, but despite this, limited data are available on the molecular status of pulmonary lesions.
Materials and Methods: 25 patients with surgically resected melanoma lung metastases were screened for BRAF, NRAS, CKIT and EGFR alterations. The results were correlated with time to lung metastasis (TLM), relapse-free survival after metastasectomy (RFS) and overall survival (OS).
Results: BRAF or NRAS were mutated in 52% and 20% of cases while CKIT was unaffected. Chromosome 7 polysomy was detected in 47% of cases with 17.5% showing EGFR amplification and concomitant BRAF mutation. NRAS mutated patients developed LM within 5 yrs from primary melanoma with larger lesions compared with BRAF (mean diameter 3.3 ± 2.2cm vs 1.9 ± 1.1cm, p = 0.2). NRAS was also associated with a shorter median RFS and OS after metastasectomy. Moreover, Cox regression analysis revealed that NRAS mutation was the only predictive factor of shorter survival from primary melanoma (p = 0.039, OR = 5.5 (1.1–27.6)).
Conclusions: Molecular characterization identifies advanced melanoma subgroups with distinct prognosis and therapeutic options. The presence of NRAS mutation was associated to a worse disease evolution.